Graves disease
Therapeutic area
Endocrinology
Rare disease
No
- Definition
- Graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism).It is caused by an abnormal immune system response that causes the thyroid gland to produce too much thyroid hormones. Graves disease is the most common cause of hyperthyroidism andoccurs mostoften in women over age 20. However, the disorder may occur at any age and may affect males as well.Treatmentmayinclude radioiodine therapy, antithyroid drugs, and/or thyroid surgery.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Graves disease
- Therapeutic area
- Endocrinology
- Graves disease
- Basedow Disease
- Graves Disease (Basedow's Disease)
- Graves Diseases
- Graves' Disease
- Graves' Hyperthyroidism
- Graves´ Disease
- Relapsed Graves' Disease
- parry disease
- Disease mechanisms
- Inflammatory
Sources for recorded values
- Severity
- Moderate
- Endocrinology
- Immunology
Sources for recorded values
- MONDO ID
- MONDO:0005364
- Parent condition
- MONDO:0001104
Related records
Broader conditions (16)
- Autoimmune disease
- Autoimmune disorder of endocrine system
- Autoimmune thyroid disease
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Endocrine system disorder
- Goiter
- Human disease
- Hyperthyroidism
- Immune system disorder
- Inflammatory disease
- Primary hyperthyroidism
- Thyroid gland disorder
- Thyroiditis
- Toxic diffuse goiter
Narrower conditions (1)
- Pediatric-onset Graves disease
Trials (162)
- A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
- A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease
- A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
- A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
- A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease
- A Prospective Evaluation of Radiofrequency Ablation in the Treatment of Relapsed Graves' Disease.
- A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery
- A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
- A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
- A Study of GensSci098 in Subjects With Graves' Disease
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
- A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
- A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
- Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up
- Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
Approved drugs (4)
- Ipodate
- Ipodate calcium
- Ipodate sodium
- Teprotumumab
Drugs in development (21)
- Alfacalcidol Phase 2
- Batoclimab Phase 2
- Carbimazole Phase 3
- Cholestyramine Phase 3
- Dexamethasone Phase 1
- Efgartigimod alfa Phase 3
- Ergocalciferol Phase 2
- Iodine Phase 3
- Iscalimab Phase 2
- Levothyroxine Phase 2
- Methimazole Phase 2
- Methylprednisolone Phase 1
- Mycophenolate mofetil Phase 2
- Mycophenolate mofetil hydrochloride Phase 2
- Potassium iodide Phase 3
- Prednisolone Phase 3
- Propylthiouracil Phase 3
- Rilzabrutinib Phase 2
- Rituximab Phase 1
- Sirolimus Phase 2
Other linked drugs (2)
- Selenium
- Tositumomab